Taro Pharmaceutical IndusTARO
13F holders, Q3 2024 (September 30)6holders −10
0new positions
10sold out
$1.36avg. 13F price*
At the end of Q3 2024, 6 institutions reported holding Taro Pharmaceutical Indus (TARO) in their 13F filings, down 10 from Q2 2024. 0 opened new positions and 10 sold out. The largest holders were MassMutual Private Wealth & Trust, FSB ($3K), Parallel Advisors, LLC ($0) and Lindbrook Capital, LLC ($0).
- Company
- Taro Pharmaceutical Indus
- CUSIP
- M8737E108
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 10 | $29.1M |
All 13F filers, Q2 2024 → Q3 2024: 677,459 shares sold, net −677,459 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| MassMutual Private Wealth & Trust, FSB | 0.00% | No change | 76 | $3K |
| Parallel Advisors, LLC | 0.00% | No change | 19 | $0 |
| Lindbrook Capital, LLC | 0.00% | No change | 142 | $0 |
| Red Tortoise LLC | 0.00% | No change | 40 | $0 |
| Farther Finance Advisors, LLC | 0.00% | No change | 126 | $0 |
| LRI Investments, LLC | 0.00% | No change | 2,000 | $0 |
"% of holder's portfolio" is TARO's weight in each manager's 13F, not the share of Taro Pharmaceutical Indus the manager owns.